A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
Identificadores
Identificadores
Fecha de publicación
2011Título de revista
INVESTIGATIONAL NEW DRUGS
Tipo de contenido
Artigo